Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline
Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’...
Radio and PodcastLive Radio & Podcasts
Science & Medicine
BioCentury This Week
A trusted and essential partner to the biopharmaceutical industry, providing 27 years of in-depth research, analysis and data on innovation and excellence —from biology to the patient.
BioCentury This Week Podcast Guide
Listen to BioCentury This Week, a Science & Medicine podcast by BioCentury. Stream 382 episodes in English, follow new audio stories, and play episodes online on Radio and Podcast.
Show Topic
Browse this show under Science & Medicine podcasts.
Episodes
20 episodes are loaded now from a catalog of 382. More episodes can be opened from this page.
Discover More
Explore Science & Medicine podcasts, South Korea podcasts and English podcasts.
Episodes
20 of 382 episodes
Ep. 371 - Moving faster at the academia-industry interface
Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too. From...
Ep. 370 - Calmer waters for FDA; Servier, Lilly deals
FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On...
Ep. 369 - ASCO advances, China innovation & U.S. science under threat
Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the late...
Ep. 368 - ASCO Preview, China Policy, ADC Linkers
At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight...
Ep. 367 - FDA, obesity targets and the rise of DACs
Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the la...
Ep. 366 - Europe's need for speed: Bio€quity takeaways
China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCent...
Ep. 365 - Thin ice for Makary, redosing AAVs
Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commis...
Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies
UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candi...
Ep. 363 - New targets at AACR, biopharma deals, Kurma fund
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the fo...
Ep. 362 - AACR: Data and de-risking
Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Researc...
Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers
The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDA...
Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar polici...
Ep. 359 - 2Q markets preview, tariffs and biotech takeouts
Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing...
Ep. 358 - Europe's biotech challenge
Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed t...
Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision
A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podc...
Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCe...
Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline
Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to...
Ep. 354 - East-West Summit Takeaways
Biotechs in South Korea and other regions of Asia outside of China need to lean into innovation to distinguish themselves from their Chinese...
Ep. 353 - Prasad Departure and Future of Fibrosis Therapies
The second ousting of Vinay Prasad from FDA in the past eight months won’t lead to major changes at the agency, other than selecting a succe...